Literature DB >> 2889438

Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality.

J L Waddington1, H A Youssef, C Dolphin, A Kinsella.   

Abstract

Little is known of factors that, on an individual basis, confer vulnerability to the emergence of involuntary movements (tardive dyskinesia) during long-term neuroleptic treatment. In this study of 88 chronic schizophrenic inpatients, 22 variables (four demographic, 14 medication history, and four features of illness) were compared for any association(s) with the presence, by differing topographies and criteria of abnormality, and severity of involuntary movements. Irrespective of the criterion used, the presence of marked cognitive dysfunction-muteness bore a consistent and highly significant primary association with both the presence and the overall severity of orofacial dyskinesia; no such association was found in relation to the presence of limb-truncal dyskinesia. Flattening of affect was the only other variable consistently associated with the presence of orofacial movements. The reliability and prominence of the association between the presence of orofacial, but not of limb-truncal, movements and cognitive dysfunction-negative symptoms suggest that these varying topographies may not constitute a unitary syndrome. This strong association, not with indexes of neuroleptic exposure but rather with features of the illness for which that treatment was prescribed, suggests some neurologic process, more subtle than may previously have been appreciated, as a vulnerability factor of some importance. In schizophrenia it appears to be intimately related to the disease process.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889438     DOI: 10.1001/archpsyc.1987.01800220077011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  15 in total

1.  Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.

Authors:  L Peacock; T Solgaard; H Lublin; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia.

Authors:  J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables.

Authors:  O Gureje
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-12       Impact factor: 10.154

4.  Involuntary orofacial movements in hospitalised patients with mental handicap or epilepsy: relationship to developmental/intellectual deficit and presence or absence of long-term exposure to neuroleptics.

Authors:  H A Youssef; J L Waddington
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

Review 5.  Effect of neuroleptics on positive and negative symptoms and the deficit state.

Authors:  J Angst; H H Stassen; B Woggon
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Chronic neuroleptic effects on spatial reversal learning in monkeys.

Authors:  E D Levin; L M Gunne
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Dementia as a complication of schizophrenia.

Authors:  P J de Vries; W G Honer; P M Kemp; P J McKenna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

Review 8.  The ageing brain, neuroleptic drugs and the enigma of schizophrenia.

Authors:  J L Waddington
Journal:  Ir J Med Sci       Date:  1988-05       Impact factor: 1.568

9.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

10.  Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia.

Authors:  Jing Qin Wu; Da Chun Chen; Yun Long Tan; Shu Ping Tan; Li Hui; Men Han Lv; Jair C Soares; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-07-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.